{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:45:33Z","timestamp":1770435933600,"version":"3.49.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,15]]},"DOI":"10.2146\/ajhp100322","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T18:21:38Z","timestamp":1309458098000},"page":"1307-1319","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacotherapy of fibromyalgia"],"prefix":"10.1093","volume":"68","author":[{"given":"Laura M.","family":"Traynor","sequence":"first","affiliation":[{"name":"School of Pharmacy, Concordia University Wisconsin (CUW), Mequon; at the time of writing she was Assistant Professor, College of Pharmacy, University of Minnesota (UM), Duluth"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher N.","family":"Thiessen","sequence":"additional","affiliation":[{"name":"Gateway Family Health Clinic, Ltd., Moose Lake, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Traynor","sequence":"additional","affiliation":[{"name":"School of Pharmacy, CUW; at the time of writing, he was Assistant Professor, College of Pharmacy, UM, Duluth"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041106045502600_b1-0681307","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.1780291110","article-title":"A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia","volume":"29","author":"Goldenberg","year":"1986","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b2-0681307","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jhmas\/38.1.5","article-title":"The development of the concept of fibrositis","volume":"38","author":"Reynolds","year":"1983","journal-title":"J Hist Med Allied Sci"},{"key":"key\n\t\t\t\t2019041106045502600_b3-0681307","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.rdc.2009.06.006","article-title":"From fibrositis to functional somatic syndromes to a bell-shaped curve of pain and sensory sensitivity: evolution of a clinical construct","volume":"35","author":"Ablin","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t2019041106045502600_b4-0681307","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1533-2500.2008.00190.x","article-title":"Fibromyalgia: harmonizing science with clinical practice considerations","volume":"8","author":"Perrot","year":"2008","journal-title":"Pain Pract"},{"key":"key\n\t\t\t\t2019041106045502600_b5-0681307","article-title":"Fibromyalgia","volume-title":"Kelley\u2019s textbook of rheumatology","author":"Wolfe","year":"2008","edition":"8th ed"},{"key":"key\n\t\t\t\t2019041106045502600_b6-0681307","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b7-0681307","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780380104","article-title":"The prevalence and characteristics of fibromyalgia in the general population","volume":"38","author":"Wolfe","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b8-0681307","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11916-008-0067-5","article-title":"Pragmatic consideration of recent randomized, placebo-controlled clinical trials for treatment of fibromyalgia","volume":"12","author":"Holman","year":"2008","journal-title":"Curr Pain Headache Rep"},{"key":"key\n\t\t\t\t2019041106045502600_b9-0681307","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11916-003-0035-z","article-title":"Epidemiology of fibromyalgia","volume":"7","author":"Neumann","year":"2003","journal-title":"Curr Pain Headache Rep"},{"key":"key\n\t\t\t\t2019041106045502600_b10-0681307","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/11313650-000000000-00000","article-title":"Societal and patient burden of fibromyalgia syndrome","volume":"27","author":"Annemans","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"key\n\t\t\t\t2019041106045502600_b11-0681307","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1742-1241.2007.01480.x","article-title":"Characteristics and health care costs of patients with fibromyalgia syndrome","volume":"61","author":"Berger","year":"2007","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t2019041106045502600_b12-0681307","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2673","article-title":"Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study","volume":"11","author":"Sicras-Mainar","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019041106045502600_b13-0681307","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jpain.2009.03.012","article-title":"Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia","volume":"10","author":"White","year":"2009","journal-title":"J Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b14-0681307","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.23265","article-title":"Health economic consequences related to the diagnosis of fibromyalgia syndrome","volume":"58","author":"Annemans","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b15-0681307","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3949\/ccjm.76a.08062","article-title":"New developments in the diagnosis of fibromyalgia syndrome: say goodbye to tender points?","volume":"76","author":"Wilke","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"key\n\t\t\t\t2019041106045502600_b16-0681307","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0307-742X(21)00264-2","article-title":"\u201cFibrositis\u201d is a disorder of pain modulation","volume":"5","author":"Smythe","year":"1979","journal-title":"Clin Rheum Dis"},{"key":"key\n\t\t\t\t2019041106045502600_b17-0681307","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0049-0172(81)90096-2","article-title":"Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched controls","volume":"11","author":"Yunus","year":"1981","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b18-0681307","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3899\/jrheum.080468","article-title":"Accuracy of the diagnosis of fibromyalgia by family physicians: is the pendulum shifting?","volume":"36","author":"Shlyfer","year":"2009","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b19-0681307","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-146-10-200705150-00006","article-title":"Narrative review: the pathophysiology of fibromyalgia","volume":"146","author":"Abeles","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041106045502600_b20-0681307","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.rdc.2008.04.003","article-title":"The physiology of pain mechanisms: from the periphery to the brain","volume":"34","author":"Marchand","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t2019041106045502600_b21-0681307","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaut.2006.09.004","article-title":"Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle","volume":"27","author":"Ablin","year":"2006","journal-title":"J Autoimmun"},{"key":"key\n\t\t\t\t2019041106045502600_b22-0681307","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.semarthrit.2006.12.009","article-title":"Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes","volume":"36","author":"Yunus","year":"2007","journal-title":"Semin Arthritis Rheum"},{"issue":"(suppl 1)","key":"key\n\t\t\t\t2019041106045502600_b23-0681307","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/hup.1029","article-title":"Fibromyalgia\u2014pathways and neurotransmitters","volume":"24","author":"Stahl","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"key\n\t\t\t\t2019041106045502600_b24-0681307","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.21191","article-title":"A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications","volume":"52","author":"Holman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b25-0681307","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.rdc.2009.05.009","article-title":"Clinical manifestations and diagnosis of fibromyalgia","volume":"35","author":"Bennett","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t2019041106045502600_b26-0681307","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11916-001-0021-2","article-title":"Classification, epidemiology, and natural history of fibromyalgia","volume":"5","author":"White","year":"2001","journal-title":"Curr Pain Headache Rep"},{"key":"key\n\t\t\t\t2019041106045502600_b27-0681307","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1213\/00000539-199912000-00038","article-title":"The Pain Visual Analog Scale; is it linear or nonlinear?","volume":"89","author":"Myles","year":"1999","journal-title":"Anesth Analg"},{"key":"key\n\t\t\t\t2019041106045502600_b28-0681307","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","article-title":"Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with noncancer pain","volume":"20","author":"Keller","year":"2004","journal-title":"Clin J Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b29-0681307","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"issue":"(suppl 39)","key":"key\n\t\t\t\t2019041106045502600_b30-0681307","first-page":"S154","article-title":"The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses","volume":"23","author":"Bennett","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b31-0681307","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"key\n\t\t\t\t2019041106045502600_b32-0681307","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures","volume":"27","author":"Hurst","year":"2004","journal-title":"J Manipulative Physiol Ther"},{"key":"key\n\t\t\t\t2019041106045502600_b33-0681307","first-page":"217","article-title":"Clinical global impressions","volume-title":"ECDEU assessment manual for psycho-pharmacology","author":"Guy","year":"1976"},{"key":"key\n\t\t\t\t2019041106045502600_b34-0681307","first-page":"235","article-title":"Sleep measures","volume-title":"Measuring functioning and well-being: the Medical Outcomes Study approach","author":"Hays","year":"1992"},{"key":"key\n\t\t\t\t2019041106045502600_b35-0681307","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric research and practice","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"key\n\t\t\t\t2019041106045502600_b36-0681307","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/art.1780230203","article-title":"Measuring health status in arthritis: the Arthritis Impact Measurement Scales","volume":"23","author":"Meenan","year":"1980","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b37-0681307","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"Beck Depression Inventory (BDI)","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t2019041106045502600_b38-0681307","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","article-title":"The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue","volume":"39","author":"Smets","year":"1995","journal-title":"J Psychosom Res"},{"key":"key\n\t\t\t\t2019041106045502600_b39-0681307","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pain.2009.05.014","article-title":"Treatment of fibromyalgia syndrome with gabapentin and pregabalin\u2014a meta-analysis of randomized controlled trials","volume":"145","author":"Hauser","year":"2009","journal-title":"Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b40-0681307","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.080734","article-title":"The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial","volume":"36","author":"Mease","year":"2009","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b41-0681307","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","article-title":"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial","volume":"30","author":"Clauw","year":"2008","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041106045502600_b42-0681307","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/13543784.11.10.1437","article-title":"Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?","volume":"11","author":"Lawson","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041106045502600_b43-0681307","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/rheumatology\/ken317","article-title":"Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy","volume":"47","author":"Nishishinya","year":"2008","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019041106045502600_b44-0681307","first-page":"697","article-title":"A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures","volume":"19","author":"Heymann","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b45-0681307","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/ard.44.11.752","article-title":"Imipramine for the treatment of fibrositis: a therapeutic trial","volume":"44","author":"Wysenbeek","year":"1985","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019041106045502600_b46-0681307","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1345\/aph.1A184","article-title":"Serotonergic agents in the treatment of fibromyalgia syndrome","volume":"36","author":"Miller","year":"2002","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041106045502600_b47-0681307","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.20076","article-title":"Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis","volume":"51","author":"Tofferi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b48-0681307","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/art.1780391111","article-title":"A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia","volume":"39","author":"Goldenberg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b49-0681307","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0002-9343(89)80623-0","article-title":"Treatment of fibrositis with fluoxetine hydrochloride (Prozac)","volume":"87","author":"Geller","year":"1989","journal-title":"Am J Med"},{"issue":"(suppl 1)","key":"key\n\t\t\t\t2019041106045502600_b50-0681307","first-page":"50","article-title":"Fibromyalgia syndrome: the pharmacological treatment options","volume":"60","author":"Sarzi-Puttini","year":"2008","journal-title":"Reumatismo"},{"key":"key\n\t\t\t\t2019041106045502600_b51-0681307","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/03009749409103725","article-title":"A double-blind placebo controlled trial of fluoxetine in fibromyalgia","volume":"23","author":"Wolfe","year":"1994","journal-title":"Scand J Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b52-0681307","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0002-9343(01)01089-0","article-title":"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia","volume":"112","author":"Arnold","year":"2002","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041106045502600_b53-0681307","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.amjmed.2006.06.006","article-title":"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia","volume":"120","author":"Patkar","year":"2007","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041106045502600_b54-0681307","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/eujp.1999.0148","article-title":"Citalopram in patients with fibromyalgia\u2014a randomized, double-blind, placebo-controlled study","volume":"4","author":"Anderberg","year":"2000","journal-title":"Eur J Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b55-0681307","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0304-3959(94)00218-4","article-title":"A randomized controlled trial of citalopram in the treatment of fibromyalgia","volume":"61","author":"N\u00f8rregaard","year":"1995","journal-title":"Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b56-0681307","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t2019041106045502600_b57-0681307","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biopsych.2003.07.006","article-title":"Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity","volume":"55","author":"Vaishnavi","year":"2004","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t2019041106045502600_b58-0681307","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0033-3182(98)71375-1","article-title":"An open clinical trial of venlafaxine treatment of fibromyalgia","volume":"39","author":"Dwight","year":"1998","journal-title":"Psychosomatics"},{"key":"key\n\t\t\t\t2019041106045502600_b59-0681307","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1345\/aph.1D112","article-title":"Venlafaxine treatment of fibromyalgia","volume":"37","author":"Sayar","year":"2003","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041106045502600_b60-0681307","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b61-0681307","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b62-0681307","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial","volume":"136","author":"Russell","year":"2008","journal-title":"Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b63-0681307","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/AJP.0b013e31819be587","article-title":"A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia","volume":"25","author":"Chappell","year":"2009","journal-title":"Clin J Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b64-0681307","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IJGM.S3979","article-title":"A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia","volume":"1","author":"Chappell","year":"2008","journal-title":"Int J Gen Med"},{"issue":"(suppl 1)","key":"key\n\t\t\t\t2019041106045502600_b65-0681307","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.622","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia","volume":"19","author":"Vitton","year":"2004","journal-title":"Human Psychopharmacol"},{"key":"key\n\t\t\t\t2019041106045502600_b66-0681307","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1503\/cmaj.051528","article-title":"Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects","volume":"174","author":"Furlan","year":"2006","journal-title":"Can Med Assoc J"},{"key":"key\n\t\t\t\t2019041106045502600_b67-0681307","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9343(03)00116-5","article-title":"Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study","volume":"114","author":"Bennett","year":"2003","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041106045502600_b68-0681307","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00124743-200010000-00004","article-title":"Efficacy of tramadol in treatment of pain in fibromyalgia","volume":"6","author":"Russell","year":"2000","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b69-0681307","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1523\/JNEUROSCI.2849-07.2007","article-title":"Decreased central mu-opioid receptor availability in fibromyalgia","volume":"27","author":"Harris","year":"2007","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t2019041106045502600_b70-0681307","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b71-0681307","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b72-0681307","first-page":"502","article-title":"A randomized, double-blind, placebo- controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b73-0681307","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","article-title":"Fibromyalgia Relapse Evaluation and Efficacy for Durability of Meaningful Relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin","volume":"136","author":"Crofford","year":"2008","journal-title":"Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b74-0681307","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/art.22457","article-title":"Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"56","author":"Arnold","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041106045502600_b75-0681307","first-page":"1418","article-title":"Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome\u2014a preliminary study","volume":"23","author":"Hrycaj","year":"1996","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b76-0681307","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med"},{"key":"key\n\t\t\t\t2019041106045502600_b77-0681307","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pnpbp.2004.08.012","article-title":"Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine","volume":"29","author":"Rico-Villademoros","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key\n\t\t\t\t2019041106045502600_b78-0681307","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0885-3924(01)00302-5","article-title":"Olanzapine for the treatment of fibromyalgia symptoms","volume":"22","author":"Kiser","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"key\n\t\t\t\t2019041106045502600_b79-0681307","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1533-2500.2006.00072.x","article-title":"Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic","volume":"6","author":"Freedenfeld","year":"2006","journal-title":"Pain Pract"},{"key":"key\n\t\t\t\t2019041106045502600_b80-0681307","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pnpbp.2006.06.023","article-title":"An open-label study of quetiapine in the treatment of fibromyalgia","volume":"31","author":"Hidalgo","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key\n\t\t\t\t2019041106045502600_b81-0681307","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00296-006-0243-z","article-title":"Use of ziprasidone in patients with fibromyalgia: a case series","volume":"27","author":"Calandre","year":"2007","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t2019041106045502600_b82-0681307","unstructured":"Clinicaltrials.gov . Pramipexole ER vs. placebo in fibromyalgia. www.clinicaltrials.gov\/ct2\/showNCT00689052?term=pramipexole+and+fibromyalgia&rank=1 (accessed 2011 May 12)."},{"key":"key\n\t\t\t\t2019041106045502600_b83-0681307","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2007.071522","article-title":"EULAR evidence-based recommendations for the management of fibromyalgia syndrome","volume":"67","author":"Carville","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019041106045502600_b84-0681307","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/ncprheum0840","article-title":"Commentary on the EULAR recommendations for the management of fibromyalgia","volume":"4","author":"Clauw","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key\n\t\t\t\t2019041106045502600_b85-0681307","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","article-title":"Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome","volume":"11","author":"Hauser","year":"2010","journal-title":"J Pain"},{"key":"key\n\t\t\t\t2019041106045502600_b86-0681307","first-page":"509","volume-title":"Antidepressant agents","author":"Batista","year":"2009","edition":"11th ed"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/14\/1307\/28349832\/ajhp1307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T07:01:09Z","timestamp":1637996469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/14\/1307\/5129385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,15]]},"references-count":86,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2011,7,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100322","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,7,15]]},"published":{"date-parts":[[2011,7,15]]}}}